Replimune is a clinical-stage biotech developing HSV-1-based oncolytic immunotherapies through its RPx platform, with multiple oncology trials and a 63,000 sq ft U.S. manufacturing facility.
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies intended to generate durable, whole-body anti-tumour immune responses in difficult-to-treat cancers. The company was founded in 2015 by experts in oncolytic immunotherapy and is headquartered in Woburn, Massachusetts, with additional sites in Framingham, Massachusetts, and Milton Park, in the United Kingdom.
Its core technology is the RPx platform, a proprietary next-generation HSV-1-based oncolytic immunotherapy system. The platform operates through a dual mechanism of action: direct destruction of tumour cells and the induction of systemic anti-tumour immune responses. The company's technical work spans oncolytic virotherapy, immuno-oncology and biologics manufacturing, and it is running multiple clinical trials across a range of oncology indications.
Alongside its clinical pipeline, Replimune operates a 63,000 square foot manufacturing facility in the United States intended to support global commercial supply. The company reports moving from laboratory research to late-stage clinical development in under a decade, an unusually compressed timeline for a modality that spans viral engineering, immunology and large-scale biologics production.
Work at Replimune sits at the intersection of viral vector design, cancer immunology and process development, with roles spanning research, clinical development and manufacturing. The company describes its focus as transforming cancer treatment for patients worldwide.
